SelectMDx is a novel urine-based risk score, which combines urinary biomarkers homeobox C6 (HOXC6) and distal-less homeobox 1 (DLX1) with traditional clinical factors such as age, PSA, digital rectal examination (DRE), prostate volume, and family history of PCa to assess the probability of risk of suffering clinical significant PCa (Gleason score ≥ 7 or Grade group ≥ 2) [17–19]. Here, HOXC6 is linked to posterior cortical atrophy.